A Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Efficacy, Safety and Tolerability of Tegaserod in Patients with Irritable Bowel Syndrome

Scandinavian Journal of Gastroenterology

Volumn 39, Issue 2, 2004, Pages 119-126

  Nyhlin, H ^b   Bang, C ^b   Elsborg, L ^b   Silvennoinen, J ^b   Holme, I ^b   Ruegg P ^b   Jones, J ^b   Wagner, A ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NONE

Author keywords

Double blind; IBS; Irritable bowel syndrome; Nordic region; Tegaserod; Zelmac

Indexed keywords

PLACEBO; TEGASEROD;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MULTICENTER STUDY; NAUSEA; PATIENT; PATIENT SATISFACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; STATISTICAL SIGNIFICANCE; SYMPTOM; TREATMENT WITHDRAWAL;

ADOLESCENT; ADULT; AGED; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INDOLES; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; PATIENT SATISFACTION; TREATMENT OUTCOME;

EID: 1342309961     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365520310006748     Document Type: Article

References (31)

1. Saito YA, Schoenfeld P, Locke GR. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol 2002;97:1910-5.
2. Icks A, Haastert B, Enck P, Rathmann W, Giani G. Prevalence of functional bowel disorders and related health care seeking: a population-based study. Z Gastroenterol 2002;40:177-83.
3. Agreus L. The epidemiology of functional gastrointestinal disorders. Eur J Surg 1998;Suppl 583:60-6.
4. Jones R, Lydeard S. Irritable bowel syndrome in the general population. Br Med J 1992;304:87-90.
5. Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut 1999;45 Suppl 2:II43-7.
6. Drossman DA, Whitehead WE, Camilleri M. Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology 1997;112:2120-37.
7. 4 receptor agonists initiate the peristaltic reflex in human, rat and guinea pig intestine. Gastroenterology 1998;115:370-80.
8. Schikowski A, Thewissen M, Mathias C, Ross HG, Enck P. Serotonin type-4 receptors modulate the sensitivity of intramural mechanoreceptive afferents in the cat rectum. Neurogastroenterol Motil 2002;14:221-7.
9. 4 receptor partial agonist, on colorectal distension in rats. Gastroenterology 2000; 118:A835.
10. 4 receptor partial agonist, tegaserod inhibits the colorectal distension-induced response of rat inferior splanchic afferents in vitro. Gastroenterology 2002; 122:A-317-A-31.
11. 4 receptor. 1. Design of a new class of agonists and receptor map of the agonist recognition site. J Med Chem 1995;38:2326-30.
12. 4 receptor. 2. Structure-activity studies of the indole carbazimidamide class of agonists. J Med Chem 1995;38:2331-8.
13. Pfannkuche HJ, Buhl T, Garnse R, Hoyer D, Mattes H, Buchheit KH. The properties of a new prokinetically active drug SDZ HTF 919. Neurogastroenterol Motil 1995;7:280.
14. Nguyen A, Camilleri M, Kost LJ, Metzger A, Sarr MG, Hanson RB, et al. SDZ HTF 919 stimulates canine colonic motility and transit in vivo. J Pharmacol Exp Ther 1997;280:1270-6.
15. 4 agonist (SDZ HTF 919) and its main metabolite in conscious dogs: effects on gastrointestinal motility and impaired gastric emptying. Gastroenterology 1998;114:A752.
16. - efflux from rat colonocytes. Gastroenterology 1999;116:A648.
17. Coffin B, Farmachidi J-P, Ruegg P, Bastie A, Bouhassira D. Tegaserod, a 5-HT4 receptor partial agonist decreases sensitivity to rectal distension in healthy subjects. Aliment Pharmacol Ther 2003;17:577-85.
18. 4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 2001;11:1745-51.
19. Baker DE. Tegaserod for the treatment of constipation-predominant irritable bowel syndrome. Rev Gastroenterol Disord 2001;1:187-98.
20. Morganroth J, Ruegg PC, Dunger-Baldauf C, Appel-Dingemanse S, Bliesath H, Lefkowitz M. Tegaserod, a 5-hydroxytrptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects. Am J Gastroenterol 2002;97:2321-7.
21. Bran S, Murray WA, Hirsch IB, Palmer JP. Long QT syndrome during high-dose cisapride. Arch Int Med 1995;155:765-8.
22. 4 agonist in the treatment of irritable bowel syndrome. Expert Opin Pharmacother 2002;3:1211-8.
23. Novick J, Milner P, Krause R, Glebas K, Bliesath H, Ligozio G, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002;16: 1877-88.
24. Tougas G, Snape Jr WJ, Otten MH, Earnest DL, Langaker KE, Pruitt RE, et al. Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2002;16:1701-8.
25. Müller-Lissner SA, Fumagalli I, Bardhan KD, Pace F, Pecher E, Nault B, et al. Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001;15:1655-66.
26. Kellow J, Lee OY, Chang FY, Thongsawat S, Mazlam MZ, Yuen H, et al. An Asia-Pacific, double-blind, placebo-controlled, randomised study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003; 52:671-6.
27. The Rome II Modular Questionnaire. In: Drossman DA, Corazziari E, Talley NJ, Thompson WG, Whitehead W, editors. Rome II - The Functional Gastrointestinal Disorders; Diagnosis, Pathophysiology and Treatment: A Multinational Consensus. McLean VA: Degnon Associates 2000; 360.
28. Committee for Proprietary Medicinal Products (CPMP). The European Agency for the Evaluation of Medicinal Products. Points to consider on the evaluation of medicinal products for the treatment of irritable bowel syndrome. London, UK; 2003.
29. Chatellier G, Zapletal E, Lemaitre D, Menard J, Degoulet P. The number needed to treat a clinically useful nomogram in its proper context. Br Med J 1966;312:426-9.
30. Harding JP, Hamm LR, Ehsanullah RSB, Heath AT, Sorrells SC, Haw J, Dukes GE, Wolfe SG, Mangel AW, Northcutt AR. Use of a novel electronic data collection system in multicenter studies of irritable bowel syndrome. Aliment Pharmacol Ther 1997;11: 1073-6.
31. Spiller RC. Problems and challenges in the design of irritable bowel syndrome clinical trials: experience from published trials. Am J Med 1999;107:915-975.